Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Rich

Showing results (451-460 of 475) with videos related to

Pageof 48
Sort By:
Medrxiv : the Preprint Server for Health Sciences|January 31, 2024
Effectiveness of a bedaquiline, linezolid, clofazimine "core" for multidrug-resistant tuberculosisChengbo Zeng, Miguel A Hernán, Letizia Trevisi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 12, 2026
Comparison of three linezolid management strategies for peripheral neuropathy in multidrug- or rifampicin-resistant tuberculosis treatment: a target trial emulationMatthew Romo, Allison LaHood, Carole D Mitnick, et al.
The European Respiratory Journal|June 18, 2021
All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settingsPalwasha Y Khan, Molly F Franke, Catherine Hewison, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 22, 2023
Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed DrugsIsmat Lotia Farrukh, Nathalie Lachenal, Malik M Adenov, et al.
Plos One|March 22, 2013
Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortalityCarole D Mitnick, Molly F Franke, Michael L Rich, et al.
Plos Medicine|October 7, 2025
Changes in child mortality and population health following 10 years of health systems strengthening in rural Madagascar: A longitudinal cohort studyAndres Garchitorena, Ann C Miller, Hobisoa L Razanadranaivo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 14, 2022
Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB CohortCatherine Hewison, Uzma Khan, Mathieu Bastard, et al.
American Journal of Respiratory and Critical Care Medicine|February 21, 2023
Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant TuberculosisLetizia Trevisi, Miguel A Hernán, Carole D Mitnick, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 4, 2022
Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line DrugsHelena Huerga, Uzma Khan, Mathieu Bastard, et al.
The European Respiratory Journal|October 27, 2018
ERS statement on harmonised standards for lung cancer registration and lung cancer services in EuropeAnna L Rich, David R Baldwin, Paul Beckett, et al.
Pageof 48

Showing results (451-460 of 475) with videos related to

Sort By:
Pageof 48
Medrxiv : the Preprint Server for Health Sciences|January 31, 2024
Effectiveness of a bedaquiline, linezolid, clofazimine "core" for multidrug-resistant tuberculosisChengbo Zeng, Miguel A Hernán, Letizia Trevisi, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 12, 2026
Comparison of three linezolid management strategies for peripheral neuropathy in multidrug- or rifampicin-resistant tuberculosis treatment: a target trial emulationMatthew Romo, Allison LaHood, Carole D Mitnick, et al.
The European Respiratory Journal|June 18, 2021
All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settingsPalwasha Y Khan, Molly F Franke, Catherine Hewison, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 22, 2023
Pregnancy and Birth Outcomes in Patients With Multidrug-Resistant Tuberculosis Treated With Regimens That Include New and Repurposed DrugsIsmat Lotia Farrukh, Nathalie Lachenal, Malik M Adenov, et al.
Plos One|March 22, 2013
Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortalityCarole D Mitnick, Molly F Franke, Michael L Rich, et al.
Plos Medicine|October 7, 2025
Changes in child mortality and population health following 10 years of health systems strengthening in rural Madagascar: A longitudinal cohort studyAndres Garchitorena, Ann C Miller, Hobisoa L Razanadranaivo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 14, 2022
Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB CohortCatherine Hewison, Uzma Khan, Mathieu Bastard, et al.
American Journal of Respiratory and Critical Care Medicine|February 21, 2023
Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant TuberculosisLetizia Trevisi, Miguel A Hernán, Carole D Mitnick, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 4, 2022
Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line DrugsHelena Huerga, Uzma Khan, Mathieu Bastard, et al.
The European Respiratory Journal|October 27, 2018
ERS statement on harmonised standards for lung cancer registration and lung cancer services in EuropeAnna L Rich, David R Baldwin, Paul Beckett, et al.
Pageof 48